[Antibacterial therapy outside of Pseudomonas aeruginosa]

Area of Science:

• Pediatric Pulmonology
• Infectious Diseases
• Microbiology

Background:

• * *Staphylococcus aureus* (SA) and *Hemophilus influenzae* are key pathogens in infants with cystic fibrosis (CF).
• * SA historically caused significant mortality in CF and may predispose to *Pseudomonas aeruginosa* infection.
• * The precise mechanisms linking SA to CF pathogenesis remain incompletely understood.

Purpose of the Study:

• * To review the role of SA in CF pathogenesis.
• * To discuss current treatment strategies for SA infections in CF patients.
• * To address the challenges posed by methicillin-resistant *Staphylococcus aureus* (MRSA) in CF.

Main Methods:

• * Literature review of SA and CF pathogenesis.
• * Analysis of treatment approaches for SA exacerbations.
• * Discussion of emerging MRSA strains and management.

Main Results:

• * SA contributes to early respiratory tract damage in CF infants.
• * Prophylactic antibiotic use for SA is debated due to unproven efficacy and potential for promoting *Pseudomonas aeruginosa* growth.
• * Oral antibiotics are commonly used for exacerbations, but evidence from controlled trials is limited.
• * Methicillin-resistant *Staphylococcus aureus* (MRSA) is an increasing concern, complicating treatment.

Conclusions:

• * SA plays a critical role in early CF lung disease progression.
• * Effective management strategies for SA, especially MRSA, are crucial in CF care.
• * Further research is needed to clarify the benefits of prophylactic antibiotics and optimize treatment regimens.